2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry
Silverberg J, Calimlim B, Grada A, Bunick C, Gooderham M, Shi V, Obi C, Knapp K, Munoz B, Crawford J, Paller A. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. Journal Of Dermatological Treatment 2024, 35: 2428729. PMID: 39662888, DOI: 10.1080/09546634.2024.2428729.Peer-Reviewed Original Research
2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study
Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.Peer-Reviewed Original ResearchConceptsBSA involvementCongenital ichthyosisHigher DLQIIgA responsesTreatment successControl studyDermatology Life Quality Index scoresBody surface area involvementDose-limiting adverse effectGlobal assessmentLife Quality Index scoresInvestigator's Global AssessmentSurface area involvementProportion of participantsRating Scale scoresSystemic retinoid treatmentYears of ageQuality Index scoresCharacteristics of participantsIgA respondersBaseline demographicsEfficacy endpointMedian ageArea involvementScale score